Featured Research

from universities, journals, and other organizations

Scientists discover endogenous dendritic cell-derived interleukin-27 promotes tumor growth

Date:
May 1, 2014
Source:
Federation of American Societies for Experimental Biology
Summary:
The groundwork has been laid for the development of novel tumor therapies that may help rid the body of cancer by inhibiting the recruitment of a specific suppressive immune cell type called 'regulatory T-cells.' "Our study not only provides a new insight into the effects of interleukin-27 in regulatory T-cell biology, but also greatly improves our understanding of the physiological functions of interleukin-27, especially in tumor immunology," said one researcher.

In a new report published in the Journal of Leukocyte Biology, scientists lay the groundwork for the development of novel tumor therapies that may help rid the body of cancer by inhibiting the recruitment of a specific suppressive immune cell type called "regulatory T-cells." The approach described in the report shows that an immune molecule, called interleukin-27, promotes the recruitment of regulatory T-cells. This suggests that by stopping IL-27's immunosuppressive function, cancer therapies can more effectively activate other T-cells to attack and destroy cancer tumors.

"Our study not only provides a new insight into the effects of interleukin-27 in regulatory T-cell biology, but also greatly improves our understanding of the physiological functions of interleukin-27, especially in tumor immunology," said Siyuan Xia, a researcher involved in the work from the State Key Laboratory of Medicinal Chemical Biology, College of Life Sciences, Nankai University, Tianjin, China. "We hope our study could shed new light on developing novel interventional therapies by targeting regulatory T-cells in cancer patients."

Scientists made this discovery by using mice deficient in a specific subunit of interleukin-27 called p28. They compared the tumor infiltrating lymphocytes between interleukin-27 p28 deficient mice and normal mice, and through their experiments, found a significant decrease of regulatory T cells, and other key immune mediators in the absence of interleukin-27 p28.

"Suppressive and regulatory pathways in the immune system are incredibly important for normal health and preventing autoimmunity," said John Wherry, Ph.D., Deputy Editor of the Journal of Leukocyte Biology. "However, these pathways also get exploited by cancer to prevent immune responses leading to cancer progression. The current studies point to an important regulatory network centered on interleukin-27 that could be targeted to improve immunity to cancer in humans."


Story Source:

The above story is based on materials provided by Federation of American Societies for Experimental Biology. Note: Materials may be edited for content and length.


Journal Reference:

  1. S. Xia, J. Wei, J. Wang, H. Sun, W. Zheng, Y. Li, Y. Sun, H. Zhao, S. Zhang, T. Wen, X. Zhou, J.-X. Gao, P. Wang, Z. Wu, L. Zhao, Z. Yin. A requirement of dendritic cell-derived interleukin-27 for the tumor infiltration of regulatory T cells. Journal of Leukocyte Biology, 2014; 95 (5): 733 DOI: 10.1189/jlb.0713371

Cite This Page:

Federation of American Societies for Experimental Biology. "Scientists discover endogenous dendritic cell-derived interleukin-27 promotes tumor growth." ScienceDaily. ScienceDaily, 1 May 2014. <www.sciencedaily.com/releases/2014/05/140501101131.htm>.
Federation of American Societies for Experimental Biology. (2014, May 1). Scientists discover endogenous dendritic cell-derived interleukin-27 promotes tumor growth. ScienceDaily. Retrieved September 17, 2014 from www.sciencedaily.com/releases/2014/05/140501101131.htm
Federation of American Societies for Experimental Biology. "Scientists discover endogenous dendritic cell-derived interleukin-27 promotes tumor growth." ScienceDaily. www.sciencedaily.com/releases/2014/05/140501101131.htm (accessed September 17, 2014).

Share This



More Health & Medicine News

Wednesday, September 17, 2014

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

President To Send 3,000 Military Personnel To Fight Ebola

President To Send 3,000 Military Personnel To Fight Ebola

Newsy (Sep. 16, 2014) President Obama is expected to send 3,000 troops to West Africa as part of the effort to contain Ebola's spread. Video provided by Newsy
Powered by NewsLook.com
Man Floats for 31 Hours in Gulf Waters

Man Floats for 31 Hours in Gulf Waters

AP (Sep. 16, 2014) A Texas man is lucky to be alive after he and three others floated for more than a day in the Gulf of Mexico when their boat sank during a fishing trip. (Sept. 16) Video provided by AP
Powered by NewsLook.com
Ivorians Abandon Monkey Pets in Fear Over Ebola Virus

Ivorians Abandon Monkey Pets in Fear Over Ebola Virus

AFP (Sep. 16, 2014) Since the arrival of Ebola in Ivory Coast, Ivorians have been abandoning their pets, particularly monkeys, in the fear that they may transmit the virus. Duration: 00:47 Video provided by AFP
Powered by NewsLook.com
Study Links Male-Pattern Baldness To Prostate Cancer

Study Links Male-Pattern Baldness To Prostate Cancer

Newsy (Sep. 16, 2014) New findings suggest men with a certain type of baldness at age 45 are 39 percent more likely to develop aggressive prostate cancer. Video provided by Newsy
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:

Breaking News:
from the past week

In Other News

... from NewsDaily.com

Science News

Health News

    Environment News

      Technology News



      Save/Print:
      Share:

      Free Subscriptions


      Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

      Get Social & Mobile


      Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

      Have Feedback?


      Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
      Mobile: iPhone Android Web
      Follow: Facebook Twitter Google+
      Subscribe: RSS Feeds Email Newsletters
      Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins